IVRS AB and NIAC Consortium Awarded Eurostars Grant for RCC Drug Development

IVRS

IVRS AB is proud to announce its key role in the NIAC consortium, which has been awarded a €1.36 million Eurostars grant to advance innovative research in renal cell carcinoma (RCC).

As part of this initiative, IVRS AB will apply its cutting-edge in vivo RCC models and whole-body 3D imaging technology to assess a novel inhibitor developed by AtG Therapeutics. This promising therapeutic has the potential to provide new hope for patients resistant to existing treatments.

With a strong commitment to accelerating oncological drug development, IVRS AB focuses on discovering new solutions for tumor progression and metastasis. This collaboration, alongside AtG Therapeutics, Doppl SA, and the University of Bern, exemplifies the impact of partnerships in driving transformative innovation in healthcare.

To learn more about IVRS AB’s work and its contributions to the NIAC project, visit: www.ivrs.se